What is the role of beta-2 microglobulin and C-reactive protein (CRP) testing in the workup of multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Beta-2 microglobulin is a surrogate marker for the overall body tumor burden. The level of beta-2 microglobulin is increased in patients with renal insufficiency without MM, which is one reason that it is a useful prognosticator in MM. [24] (See Prognosis.) Patients with MM and impaired renal function have a worse prognosis.

C-reactive protein (CRP) is a surrogate marker of interleukin (IL)-6 activity. IL-6 is often referred to as the plasma cell growth factor. Like beta-2 microglobulin, CRP is useful for prognostication. [24] (See Prognosis.)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!